Trinity Biotech (TRIB) Reports Q4 Loss of $0.23/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Trinity Biotech Announces Q3 2022 Financial Results
December 15, 2022 9:05 AM ESTDUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Companys results for the quarter ended September 30, 2022.
Summary Highlights:
Total revenues for Q3 2022 were $19.5m. Excluding our Covid focused PCR Viral Transport Media (VTM) products, Q3 2022 revenues of $19.2m were marginally higher by 2% compared to Q3 2021 and were up 6% compared to Q2 2022.A strong YoY 30% increase in revenues attributable to both our Haemoglobins and Fitzgerald... More